Abstract YO15
Case summary
Concurrent Atezolizumab-Radiotherapy in Locally Recurrent Urinary Bladder Carcinoma: A Case Report
Abstract
Locally recurrent urinary bladder carcinoma is difficult to manage and cytotoxic chemotherapy regimens offer low response rates with high toxicities. Immune checkpoint inhibitors represent new opportunity for effective management of these patients. Atezolizumab produced durable responses, improved survival and tolerability in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma. High-dose radiation, in addition to its direct cell killing, could influence immune response. Combination of immune checkpoint inhibitor and radiation therapy have the potential to provide a synergistic effect in treating GU malignancies. This is a case of locally recurrent urinary bladder carcinoma responding to Atezolizumab plus radiotherapy.
A 66 year old male had 2 months history gross hematuria. Pelvic MRI showed a left-sided 3.4 x 2.4 x 2.8 cm urinary bladder tumor. A transurethral resection of bladder tumor (TURBT) was done and histopathology revealed high-grade urothelial carcinoma with glandular metaplasia and invasion of the lamina propria. The patient had a prolonged hospitalization due to subsequent emergency exploratory laparotomy secondary to ruptured peptic ulcer disease complicated by wound dehiscence and hospital-acquired pneumonia. 5 months from TURBT, re-evaluation KUB ultrasound showed mucosal irregularity (1.6 x 1.6 x 1.3 cm) in left side of Urinary bladder with a hypoechoic mass adjacent to it. Patient refused further work-up. At this time, he was also being treated for recurrent parapneumonic effusion. Radical cystectomy was contemplated but due to the patient’s condition the patient was deemed inoperable. Moreover, the patient refused cytotoxic chemotherapy. He thus underwent IMRT to 60 cGy concurrent with Atezolizumab 1200 mg IV every 21 days for 12 cycles. CT evaluation showed no residual or recurrent tumor. The patient remains to be asymptomatic with weight gain and on close surveillance.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract
397P - Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients
Presenter: Teerapat Ungtrakul
Session: Poster display session
Resources:
Abstract
398P - Planning for future cancer control programs in Uganda: Projections of top five cancers’ incidence in the next decade
Presenter: Judith Asasira
Session: Poster display session
Resources:
Abstract
399P - Prevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali
Presenter: Cindy Trisina
Session: Poster display session
Resources:
Abstract
400P - Female lung cancer: Emerging issue in Bangladesh
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
402P - Work-related outcomes among cancer survivors in Singapore
Presenter: Chia Jie Tan
Session: Poster display session
Resources:
Abstract
407P - Focal treatments for metastatic soft tissue sarcoma (mSTS) is associated with improved overall survival
Presenter: Ching Tso Chen
Session: Poster display session
Resources:
Abstract
408P - The Asian sarcoma consortium sarcoma preceptorship program: A program evaluation study utilizing the Kirkpatrick model (Level 1 and 2)
Presenter: Fernando Gracieux Jr.
Session: Poster display session
Resources:
Abstract
409P - Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients
Presenter: Yuhong Zhou
Session: Poster display session
Resources:
Abstract
410P - Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)
Presenter: Yu-ju Kuo
Session: Poster display session
Resources:
Abstract